EGFR and non-small cell lung carcinoma: A phase 1 clinical study (NCT02374645) conducted in China evaluated the combination of savolitinib and gefitinib (a first-generation EGFR-TKI) in patients with advanced disease EGFRm and MET amplification in NSCLC.